BRIEF-ContraVir to highlight clinical data from phase 2a study of tenofovir exalidex for treating hepatitis B
February 14, 2017 at 06:11 AM EST
* ContraVir to highlight clinical data from ongoing phase 2a study of tenofovir exalidex (TXL) for treating hepatitis B